287 related articles for article (PubMed ID: 18543783)
1. Asymmetric dimethylarginine--mechanisms and targets for therapeutic management.
Vladimirova-Kitova LG
Folia Med (Plovdiv); 2008; 50(1):12-21. PubMed ID: 18543783
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral L-arginine.
Böger GI; Rudolph TK; Maas R; Schwedhelm E; Dumbadze E; Bierend A; Benndorf RA; Böger RH
J Am Coll Cardiol; 2007 Jun; 49(23):2274-82. PubMed ID: 17560293
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Böger RH; Bode-Böger SM; Szuba A; Tsao PS; Chan JR; Tangphao O; Blaschke TF; Cooke JP
Circulation; 1998 Nov; 98(18):1842-7. PubMed ID: 9799202
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects.
Pereira EC; Bertolami MC; Faludi AA; Salem M; Bersch D; Abdalla DS
Free Radic Res; 2003 May; 37(5):529-36. PubMed ID: 12797474
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans.
Chan JR; Böger RH; Bode-Böger SM; Tangphao O; Tsao PS; Blaschke TF; Cooke JP
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1040-6. PubMed ID: 10764670
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
Bełtowski J; Kedra A
Pharmacol Rep; 2006; 58(2):159-78. PubMed ID: 16702618
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase.
Hsu CP; Zhao JF; Lin SJ; Shyue SK; Guo BC; Lu TM; Lee TS
J Am Heart Assoc; 2016 Apr; 5(4):e003327. PubMed ID: 27091343
[TBL] [Abstract][Full Text] [Related]
14. Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels.
Trocha M; Szuba A; Merwid-Lad A; Sozański T
Pharmazie; 2010 Aug; 65(8):562-71. PubMed ID: 20824955
[TBL] [Abstract][Full Text] [Related]
15. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
16. The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage.
Szlachcic A; Krzysiek-Maczka G; Pajdo R; Targosz A; Magierowski M; Jasnos K; Drozdowicz D; Kwiecien S; Brzozowski T
Curr Pharm Des; 2013; 19(1):90-7. PubMed ID: 22950506
[TBL] [Abstract][Full Text] [Related]
17. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.
Oguz A; Uzunlulu M
Int Heart J; 2008 May; 49(3):303-11. PubMed ID: 18612188
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin.
Eid HM; Eritsland J; Larsen J; Arnesen H; Seljeflot I
Atherosclerosis; 2003 Feb; 166(2):279-84. PubMed ID: 12535740
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
20. The effect of simvastatin on asymmetric dimethylarginine and flow-mediated vasodilation after optimizing the LDL level: a randomized, placebo-controlled study.
Vladimirova-Kitova LG; Deneva-Koycheva TI
Vascul Pharmacol; 2012; 56(3-4):122-30. PubMed ID: 22108444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
